Early production of HIV-1 neutralising antibodies in patients following highly active antiretroviral treatment (HAART) during primary HIV infection

Journal of Biological Regulators and Homeostatic Agents

Volumn 14, Issue 1, 2000, Pages 68-74

  Barassi, C ^a   De Santis, C ^a   Pastori, C ^a   Marraccini, P ^a   Ciuffreda, D ^a   Capiluppi, B ^a   Bressi, C ^a   Siccardi, A G ^a   Lazzarin, A ^a   Tambussi, G ^a   Lopalco, L ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

HAART; HIV 1; Humoral immunity; Neutralising antibodies; PHI

Indexed keywords

ANTIRETROVIRUS AGENT; IMMUNOGLOBULIN FRAGMENT; LAMIVUDINE; NEUTRALIZING ANTIBODY; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ADULT; ANTIBODY PRODUCTION; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; MALE; MEDICAL INFORMATION; PRIMARY INFECTION; T LYMPHOCYTE; VIREMIA; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0034457225     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. The AIDS epidemic
2. Acute human immunodeficiency virus type 1 infection
3. Biological and virologic characteristics of primary HIV infection
4. Functional T cell reconstitution and human immunodeficiency virus-1- specific cell-mediated immunity during highly active antiretroviral therapy
5. Virology and immunology of acute HIV type 1 infection
6. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy
7. HIV-specific cellular and humoral immune responses in primary HIV infection
8. Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection
9. Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies?
10. Autologous HIV-1 neutralizing antibodies: Emergence of neutralization- resistant escape virus and subsequent development of escape virus neutralizing antibodies
11. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads
12. Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants
13. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities
14. HAART and host: Balancing the response to HIV-1. Highly active antiretroviral therapy
15. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
16. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
17. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure
18. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
19. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
20. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection
21. Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection
22. Human immunodeficiency virus (HIV)-specific lgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV- seropositive persons
23. A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates
24. Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapy
25. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
26. Control of HIV despite the discontinuation of antiretroviral therapy
27. The moving target: Mechanisms of HIV persistence during primary infection
28. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp 120 retention from sCD4-sensitive isolates